The first research challenge for diamicron MR in Iranian diabetic patients

International Journal of Pharmacology

Volumn 2, Issue 3, 2006, Pages 316-319

  Iranparvar, M ^a   Sadeghi Bazargani, H ^a   Khodamoradzadeh, M ^a  

^a ARDABIL UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Diabetes; Diamicron MR; Glycosylated hemoglobin; Oral anti hyperglycemic agents; Sulfonylurea

Indexed keywords

DIAMICRON MR; GLICLAZIDE; GLUCOSE; HEMOGLOBIN A1C;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES CONTROL; DIABETIC DIET; DIET RESTRICTION; DRUG EFFICACY; DRUG RESEARCH; EXERCISE; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEMOGLOBIN DETERMINATION; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; IRAN; MALE; MAXIMUM PERMISSIBLE DOSE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 33745758567     PISSN: 18117775     EISSN: 18125700     Source Type: Journal    
DOI: 10.3923/ijp.2006.316.319     Document Type: Article

References (16)

1. Azizi, F., 2002. Change in life style to prevent major noncommunicable diseases. Iranian J. Endocrinol. Metab., 4: 80-84.
2. Buse, J.B., 1999. overview of current therapeutic options in type 2 diabetes rational for combining oral agents with Insulin therapy. Diabetes Care, 22 (Supl 3): 65-70.
3. Collier, A., H.H. Watson, A.W. Patrick, C.A. Ludlam and B.F. Clarke, 1989. Effect of glycaemic control, metformin and gliclazide on platelet density and aggregability in recently diagnosed type 2 (non-insulin-dependent) diabetic patients. Diabete Metab., 15: 420-425.
4. Defronzora, 2000. Pharmacological Therapy for type 2 diabetes. Annals of Intern. Med., 133: 73-74.
5. Drouin, P., 2000. Diamicron MR once daily is effective and well tolerated in type 2 diabetes: A double-blind, randomized, multinational study. J. Diabetes Complications, 14: 185-191.
6. Guillausseau, P.J. and W. Greb, 2001. Twenty four hour glycemic profile in type 2 diabetic patients treated with gliclazide modified release once daily: Diabetes Metab., 27: 133-137.
7. Harrower, A.D., 1985. Comparison of diabetic control in type 2 (non-insulin dependent) diabetic patients treated with different sulphonylureas. Curr. Med. Res. Opin., 9: 676-680.
8. InZucchi, S.E., 2002. Oral anti hyperglycemic therapy for type 2 diabetes. Scientific Review JAMA., 287: 360-372.
9. Jennings, P.E., N.A. Scott, A.R. Saniabadi and J.J. Belch, 1992. Effects of gliclazide on platelet reactivity and free radicals in type II diabetic patients. Clin. Assess. Metab., 41(5 Suppl 1): 36-39.
10. Noury, J. and A. Nandeuil, 1991. Comparative three-month study of the efficacies of metformin and gliclazide in the treatment of NIDDM. Diabete Metab., 17: 209-12.
11. Paes, A.H., A. Bakker and C.J. Soe-Agnie, 1997. Impact of dosage frequency on patient compliance. Diabetes Care, 20: 1512-1517.
12. Prospective Diabetes Study Group, 1998. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS). Lancet, 352: 837-853.
13. Pullar, T., A.J. Birtwell, P.G. Wiles, A. Hay and M.P. Feely, 1988. Use of a pharmacologic indicator to compare compliance with tablets prescribed to be taken once, twice, or three times daily. Clin. Pharmacol. Ther., 44: 540-545.
14. Tessier, D., K. Dawson, J.P. Tetrault, G. Bravo and G.S. Meneilly, 1994. Glibenclamide vs gliclazide in type 2 diabetes of the elderly. Diabet. Med., 11: 974-980.
15. Tessier, D., P. Maheux, A. Khalil and T. Fulop, 1999, Effects of gliclazide versus metformin on the clinical profile and lipid peroxidation markers in type 2 diabetes. Metabolism, 48: 897-903.
16. The Diabetes Control and Complications Trial Research Group, 1993. The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin dependent diabetes mellitus. NEJM, 329: 977-9869.